Arrowhead Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Revenue	1,091	829.45	3.55	240.74	243.23	138.29
Revenue Growth (YoY)	43539.24%	23258.15%	-98.52%	-1.03%	75.89%	57.16%
Gross Profit	1,091	829.45	3.55	240.74	243.23	138.29
Selling, General & Admin	157.5	138.5	113.44	104.08	132.44	85.44
Research & Development	632.92	592.6	491.19	341.66	289.3	201.88
Operating Expenses	790.41	731.1	604.63	445.74	421.74	287.32
Operating Income	300.57	98.35	-601.08	-205	-178.51	-149.04
Interest Expense	-90.22	-89.36	-32.35	-18.33	-	-
Interest & Investment Income	39.38	37.29	22.72	15.3	5.03	6.12
Other Non Operating Income (Expenses)	5.2	5.26	-1.75	1.54	0.77	2.07
EBT Excluding Unusual Items	254.92	51.53	-612.46	-206.49	-172.71	-140.85
Pretax Income	254.92	51.53	-612.46	-206.49	-172.71	-140.85
Income Tax Expense	21.35	21.42	-2.77	2.78	3.79	0
Earnings From Continuing Operations	233.57	30.11	-609.69	-209.28	-176.49	-140.85
Minority Interest in Earnings	-31.31	-31.75	10.2	4	0.43	-
Net Income	202.27	-1.63	-599.49	-205.28	-176.06	-140.85
Net Income to Common	202.27	-1.63	-599.49	-205.28	-176.06	-140.85
Shares Outstanding (Basic)	137	134	120	107	105	104
Shares Outstanding (Diluted)	138	134	120	107	105	104
Shares Change (YoY)	10.94%	11.67%	12.21%	1.26%	1.62%	3.00%
EPS (Basic)	1.48	-0.01	-5.00	-1.92	-1.67	-1.36
EPS (Diluted)	1.48	-0.01	-5.00	-1.92	-1.67	-1.36
Free Cash Flow	322.01	156.89	-604.32	-330.63	-188.91	147.75
Free Cash Flow Per Share	2.34	1.17	-5.04	-3.10	-1.79	1.42
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	27.55%	11.86%	-16927.06%	-85.16%	-73.39%	-107.77%
Profit Margin	18.54%	-0.20%	-16882.37%	-85.27%	-72.39%	-101.85%
Free Cash Flow Margin	29.52%	18.92%	-17018.31%	-137.34%	-77.67%	106.84%
EBITDA	325.65	122.27	-582.49	-192.51	-168.09	-140.77
EBITDA Margin	29.85%	14.74%	-	-79.97%	-69.11%	-101.79%
D&A For EBITDA	25.08	23.93	18.6	12.49	10.42	8.27
EBIT	300.57	98.35	-601.08	-205	-178.51	-149.04
EBIT Margin	27.55%	11.86%	-	-85.16%	-73.39%	-107.77%
Effective Tax Rate	8.37%	41.56%	-	-	-	-

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q